ReviewFrontiers in public health2022
Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges.
Review in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.Lancet (London, England) · 2024Trial
- Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.Pharmaceutics · 2026Review
- Priority implementation research for measles-rubella microarray patches identified using the Child Health and Nutrition Research Initiative methodology.Journal of global health · 2026Article
- Advances in Drug and Vaccine Delivery for Low- and Middle-Income Healthcare Programs-The Case for Replacing Multi-Dose Vials with Prefilled Single-Dose Delivery Systems.Pharmacy (Basel, Switzerland) · 2025Article
- Achieving and sustaining measles elimination in Hong Kong, from 1967 to 2024: lessons to be learnt.BMJ global health · 2025Review
- Article
- Review
- Small-area variation in child under-vaccination in India: a multilevel analysis of cross-sectional data from 36 states and Union Territories, 707 districts, and 22,349 small-area clusters.The Lancet regional health. Southeast Asia · 2025Article
- Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.Vaccines · 2024Article
- Article
- Article
- The Problem with Delaying Measles Elimination.Vaccines · 2024Review
- Possible Paths to Measles Eradication: Conceptual Frameworks, Strategies, and Tactics.Vaccines · 2024Review
- Exploring landscape of measles vaccination coverage: A step towards measles elimination goal in India.Vaccine · 2024Article
- Accelerating Global Measles and Rubella Eradication-Saving Millions of Lives, Preventing Disability, and Averting the Next Pandemic.Vaccines · 2024Article
- Article
- Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.BMJ global health · 2023Article
- Exploring potential applications of measles and rubella microarray patches (MR-MAPs): use case identification.Frontiers in public health · 2023Article
- Investing in global measles and rubella elimination is needed to avert deaths and advance health equity.The Lancet. Global health · 2022Article
- Digital Marketing: A Unique Multidisciplinary Approach towards the Elimination of Viral Hepatitis.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
Measles and rubella microarray patches (MR-MAPs) are critical in achieving measles and rubella eradication, a goal highly unlikely to meet with current vaccines presentations. With low commercial incentive to MAP developers, limited and uncertain funding, the need for investment in a novel manufacturing facility, and remaining questions about the source of antigen, product demand, and regulatory pathway, MR-MAPs are unlikely to be prequalified by WHO and ready for use before 2033. This article describes the current progress of MR-MAPs, highlights challenges and opportunities pertinent to MR-MAPs manufacturing, regulatory approval, creating demand, and timelines to licensure. It also describes activities that are being undertaken by multiple partners to incentivise investment in and accelerate the development of MR-MAPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.